Selank peptide is a synthetic heptapeptide derived from tuftsin and studied in clinical trials for anxiety reduction and cognitive support — without benzodiazepine sedation, tolerance, or dependence. It is not FDA-approved, and any evaluation is subject to provider review at TelosRX.
This selank peptide research guide covers how it works, what the clinical data actually shows, dosage protocols from published studies, and who should avoid it.
What Is Selank?
Selank (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro, also written TKPRPGP) is a synthetic analog of tuftsin, a small immune-messenger fragment naturally derived from immunoglobulin G. Researchers at Russia's Institute of Molecular Genetics modified the base tuftsin sequence by adding three amino acids at the C-terminus to extend its metabolic stability and duration of action.
It was approved in Russia in 2009 for generalized anxiety disorder (GAD). In the United States, it is not FDA-approved for any indication. As of April 2026, Selank was withdrawn from the FDA's Category 2 bulk substances nomination list — meaning it no longer holds an active compounding nomination under regulatory review. Any clinical use is strictly subject to evaluation by a licensed provider.
Its molecular weight is 751.86 g/mol. The plasma half-life is roughly 2–3 minutes after administration due to rapid hepatic clearance. Intranasal delivery bypasses this degradation by routing the peptide through olfactory nerve pathways for more direct CNS access — which is why the nasal spray route dominates the published research.
How Selank Works: The Mechanism
Selank doesn't work like a single-note sedative. It operates through at least four interconnected pathways, which together explain its unique anxiolytic-without-sedation profile:
- GABAergic modulation: Selank acts as a positive allosteric modulator at GABA-A receptors. It increases the affinity of endogenous GABA for the receptor rather than forcing the receptor open. This is a gentler mechanism than benzodiazepines, which directly enhance chloride channel activity.
- Enkephalin protection: Selank inhibits enkephalin-degrading enzymes in plasma. Enkephalins are the brain's own stress-buffering peptides — keeping them active longer contributes to Selank's anti-stress and mood-stabilizing effects.
- Monoamine modulation: Preclinical studies show upregulation of serotonin metabolism in the brainstem and modulation of dopamine concentrations. This may explain reports of improved mood and motivation alongside anxiety reduction.
- BDNF upregulation: Selank promotes brain-derived neurotrophic factor (BDNF) expression in the hippocampus. BDNF — a protein that supports neuronal growth and resilience — supports synaptic plasticity, neuronal survival, and memory consolidation.
A 2016 study published in Frontiers in Pharmacology confirmed that Selank influences gene expression in GABAergic neurotransmission pathways in rat frontal cortex tissue, providing mechanistic support for its anxiolytic profile.
What Selank Research Actually Shows
The clinical evidence base is modest but consistent. Most human trials were conducted in Russia between 2005 and 2015, which limits international generalizability but doesn't undermine the data quality of the trials themselves.
The most-cited human study enrolled 62 patients with GAD and neurasthenia in a randomized comparison against medazepam (a standard benzodiazepine). Selank reduced anxiety scores equivalently to medazepam without sedation, muscle relaxation, cognitive dulling, or motor impairment. A 2015 follow-up study of 70 patients found that combining Selank with phenazepam improved efficacy while reducing the side effect burden compared to phenazepam alone.
A 2017 study in Behavioural Neurology examined Selank combined with diazepam under chronic unpredictable mild stress in rats. Combined administration almost completely eliminated stress-induced anxiety — without increasing the motor impairment seen with diazepam alone. This suggests Selank amplifies the anxiolytic action of benzodiazepines while partially blunting their side effects.
For cognitive function, animal models and small human data suggest improvements in working memory, attention, and learning — especially in populations where cognition was impaired by dopamine disruption or chronic stress. This is the “anxiolytic nootropic” framing: Selank calms without fogging.
One less-discussed finding: immune modulation. Selank has been shown to normalize cytokine profiles — specifically IL-6 and related inflammatory markers — in patients with anxiety-related disorders, pointing toward a brain-immune axis component in its mechanism.
Selank vs. Benzodiazepines: The Real Comparison
The most clinically relevant question is how Selank compares to the current standard. Here's what the published data actually supports:
| Feature | Selank | Benzodiazepines (e.g., Xanax, Valium) |
|---|---|---|
| Anxiolytic effect | Comparable to low-dose benzos in GAD trials | Strong, rapid onset for acute anxiety |
| Sedation | Minimal to absent in available studies | Common; dose-dependent drowsiness |
| Cognitive impact | Preserved or improved in research models | Impaired attention and memory with chronic use |
| Dependence / withdrawal | No dependence signals in clinical data to date | Well-documented tolerance and dependence risk |
| FDA approval | Not FDA-approved (US) | FDA-approved for anxiety and panic disorders |
| Evidence volume | Small trials; predominantly Russian literature | Decades of large-scale international data |
Benzodiazepines remain the standard for acute, severe anxiety and panic — nothing in the Selank research challenges that. Where the comparison gets interesting is for persistent, day-to-day anxiety in people who need to stay cognitively sharp: a demanding professional, a student, someone whose responsibilities don't allow sedation at 9 a.m.
For readers curious about related neuropeptides, TelosRX has research guides on Semax — a stimulating analog from the same Russian research lineage — and Dihexa, studied for synaptic plasticity and memory consolidation.
Selank Dosage and Administration
Oral Selank doesn't work — digestive enzymes break it down before it reaches the bloodstream. The two delivery routes studied in humans are:
- Intranasal spray: The most-studied route. Each spray delivers roughly 100–150 mcg. The peptide travels along olfactory nerve pathways to reach the CNS within minutes, bypassing hepatic first-pass degradation entirely.
- Subcutaneous injection: Used in some clinic protocols with different absorption characteristics than intranasal delivery, though it introduces additional preparation and injection-site considerations.
Published Russian clinical protocols used doses ranging from roughly 200–600 mcg per administration, 1–3 times daily, in cycles of 10–21 days followed by a break period before reassessment. Preclinical animal research used 300 mcg/kg as the effective anxiolytic dose. These figures describe what has been studied — they are not prescribing recommendations.
Unlike Semax, which has a stimulating profile and is typically taken in the morning, Selank's calming effect means it can generally be dosed at any time of day. For the sleep dimension of anxiety management, DSIP (Delta Sleep-Inducing Peptide) represents a separate area of peptide research worth reviewing.
Any protocol would be evaluated and issued by a licensed provider through TelosRX's asynchronous intake process — there are no real-time consultations, just a thorough async evaluation of your health history, current medications, and clinical goals before any provider-issued prescription is considered.
Selank Side Effects and Safety
Published human studies report Selank as well-tolerated in short-term use. The most commonly reported mild effects include:
- Nasal irritation or mild burning with spray administration
- Transient headache
- Dizziness or lightheadedness at higher doses
- Temporary fatigue at the beginning of a cycle
No physical dependence, tolerance, or withdrawal syndromes have been reported in the clinical literature. In the 14-day randomized studies, tolerance was not observed. This is a meaningful structural difference from benzodiazepines, where tolerance develops quickly and discontinuation often requires a slow taper.
Less-understood risks: the FDA has flagged immunogenicity as a concern for compounded peptides generally. Immune reactions to peptide formulations — especially via injection — are theoretically possible, and long-term human safety data beyond 21-day cycles is limited. This isn't unique to Selank; it applies across the compounded peptide category.
For immune-adjacent peptide research context, the Thymosin Beta-4 research guide covers another peptide with immune-modulatory properties studied in tissue repair models.
Who Should Not Use Selank
Several populations should avoid Selank entirely or proceed only under close medical supervision:
- Pregnant or breastfeeding individuals (no safety data available)
- People with active malignancy or receiving cancer immunotherapy
- Patients with significant autoimmune conditions — lupus, multiple sclerosis, severe rheumatoid arthritis
- Individuals on complex psychiatric medication regimens (SSRIs, antipsychotics, mood stabilizers, sedatives)
- People with a history of severe allergic reactions to injectables or peptide-based compounds
- Patients with severe neurological disorders or active seizure history
Provider evaluation is not a formality. A licensed provider needs to review your medication list, medical history, and current conditions before any protocol is considered — and approval is not guaranteed regardless of how well a candidate appears to fit on paper.
Frequently Asked Questions
What is selank peptide used for?
Selank is a synthetic heptapeptide studied primarily for anxiety reduction, cognitive support, and stress resilience. In Russian clinical trials, it demonstrated anxiolytic effects comparable to low-dose benzodiazepines, with preserved or improved cognitive function and no sedation. It is not FDA-approved and is classified as a research compound in the United States.
Is selank FDA-approved?
No. Selank is not FDA-approved for any indication in the US. It was previously nominated for the FDA's Category 2 bulk substances list for compounding review, but was withdrawn from that list in April 2026. Any evaluation or protocol requires assessment by a licensed provider and operates outside FDA-approved indications.
How does selank work for anxiety?
Selank modulates GABA-A receptors as a positive allosteric modulator — increasing receptor sensitivity to endogenous GABA rather than forcing the receptor open like benzodiazepines. It also inhibits enkephalin-degrading enzymes, modulates serotonin and dopamine, and upregulates BDNF. This multi-pathway approach produces anxiolytic effects without the sedation profile of standard tranquilizers.
Can selank cause withdrawal or dependence?
Available clinical data have not shown physical dependence, tolerance, or withdrawal syndromes with Selank. This contrasts with benzodiazepines, which carry well-documented dependence and discontinuation risks. However, long-term human data beyond 21-day cycles are sparse, so this cannot be stated definitively for all use patterns or durations.
What is the selank dosage used in research?
Russian clinical research used intranasal delivery at roughly 200–600 mcg per administration, 1–3 times daily, in cycles of 10–21 days with break periods between cycles. These figures describe what has been studied — not a prescribing recommendation. Any protocol is determined by a licensed provider after a full evaluation, and approval is not guaranteed.
How long does selank take to work?
With intranasal delivery, some study participants reported changes in anxiety levels within the first few administrations. In the 62-patient GAD trial, clinically meaningful reductions in anxiety scores were observed by day 14. Most research protocols run 10–21 days before evaluating response, with individual variation based on dose, delivery route, and patient profile.
What is the difference between selank and semax?
Both are synthetic neuropeptides developed in Russia from endogenous regulatory peptides, but with distinct profiles. Selank is derived from tuftsin and is primarily anxiolytic — calming without sedation. Semax is derived from ACTH and has a more stimulating, nootropic profile used for focus, cognitive performance, and neuroprotection. They work through different pathways and are often described as complementary rather than interchangeable.
Who should not use selank?
Selank should be avoided or used only under close supervision in pregnant or breastfeeding individuals, people with active cancer or receiving immunotherapy, patients with significant autoimmune conditions, individuals on complex psychiatric drug regimens, and those with a history of severe allergic reactions to injectables or biological compounds. Provider evaluation is required before any protocol is considered.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.